Dr David Kimberlin

Dr. David Kimberlin holds the Sergio Stagno Endowed Chair in Pediatric Infectious Diseases at the University of Alabama at Birmingham, where he is Vice Chair for Clinical and Translational Research and Co-Director of the Division of Pediatric Infectious Diseases.  Dr. Kimberlin is Editor of the 2021 American Academy of Pediatrics (AAP) Report of the Committee on Infectious Diseases (Red Book).  He also was Editor of the 2018 and 2015 editions, and will be for the upcoming 2024 edition.  Since 2007, Dr. Kimberlin has served as the AAP Red Book liaison to the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP).  Through both the ACIP and the AAP Committee on Infectious Diseases, Dr. Kimberlin has been involved throughout the COVID pandemic in major decisions nationally on recommendations for use of COVID-19 vaccines across the age spectrum.

Dr. Kimberlin also is the Principal Investigator for the Collaborative Antiviral Study Group (CASG), now known as the Congenital and Perinatal Infections Consortium (CPIC).  Funded continuously by NIH/NIAID/DMID since the early 1970s, the CASG/CPIC is a network of pediatric academic medical centers that evaluates antiviral therapeutics in rare diseases with a large unmet medical need, including neonatal herpes simplex virus (HSV) infections, congenital cytomegalovirus (CMV) disease, congenital Zika syndrome, neonatal and infantile influenza infection, and neonatal enteroviral sepsis syndrome.  Dr. Kimberlin is a Past-President of the Pediatric Infectious Diseases Society (PIDS).  In 2016 he received the Ronald McDonald House Charities 2016 Medical Award of Excellence.  He has received numerous education awards.